India prepared to fight Omicron variant of coronavirus: Mandaviya

Buffer stocks of medicine and oxygen have been prepared to mitigate any crisis and 48,000 ventilators have been distributed to states, the minister said

Mansukh L Mandaviya
Union Health Minister Mansukh L Mandaviya | File photo: PTI
Press Trust of India New Delhi
2 min read Last Updated : Dec 21 2021 | 12:47 AM IST

India is prepared to fight the Omicron variant of coronavirus and the country's vaccine manufacturing capacity will be increased to 45 crore doses per month in the next two months, Health and Family Welfare Minister Mansukh Mandaviya informed Rajya Sabha on Monday.

Buffer stocks of medicine and oxygen have been prepared to mitigate any crisis and 48,000 ventilators have been distributed to states, the minister said.

Giving an update on the status of COVID-19 vaccinations in India, Mandaviya said 88 percent of the eligible population has been given the first dose and 58 percent second dose.

Speaking at a discussion in the Upper House on the situation arising out of cases of Omicron variant of COVID-19 virus in the country, the minister said it has been declared a variant of concern by the World Health Organisation, and the government is keeping a close watch on the situation.

Noting that the variant is spreading globally, Mandaviya said so far 161 cases of Omicron variant infections have been reported in the country and the government has already taken steps to tackle it.

He said the government has identified 'at risk' countries where the variant has been reported. People coming from those countries are required to take mandatory tests on arrival to India with seven days isolation at home with another testing again after seven days.

The Centre is in constant and regular touch with states and experts on the matter to understand the effect of the variant on the population, he added.

He said India's vaccine manufacturing capacity has also increased and will further rise.

At present, the capacity is 31 crore doses per month and it will be increased to 45 crore dose per month in the next two months, he said adding two more companies have submitted their vaccine data seeking emergency use authorisation.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Dec 20 2021 | 6:21 PM IST

Next Story